33 results about "Hyperammonemia" patented technology

The present invention relates to newborn screening kits, methods, stable isotopically-labeled internal standards or internal standard solution for high throughput screening and analysis of metabolic disorders using liquid chromatography mass spectrometry (LC-MS) are provided. The metabolic disorders can be amino acid, organic acid or fatty acid oxidation disorders, and particularly urea cycle disorders or deficiencies, hyperammonemia, Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH), and / or argininosuccinic aciduria. The newborn screening kits, methods, stable isotopically-labeled internal standards or internal standard solution are particularly useful for newborn screening (NBS) of metabolic disorders.

Viral vectors comprising engineered hOTC DNA and RNA sequences are provided which when delivered to a subject in need thereof are useful for treating hyperammonemia, ornithine transcarbamylase transcarbamylase deficiency and symptoms associated therewith. Also provided are methods of using hOTC for treatment of liver fibrosis cirrhosis in OTCD patients by administering hOTC.

The invention features the use of a defined microbial consortia for the replacement of a gut microbiome associated with disease. In particular, the invention provides for the treatment of hyperammonemia, Clostridium difficile colitis, hepatic encephalopathy associated with cirrhosis, and inflammatory bowel disease.

The present invention is directed to a liposome composition for use in the peritoneal dialysis of patients suffering from endogenous or exogenous toxicopathies, wherein the pH within the liposomes differs from the pH in the intraperitoneal cavity and wherein the pH within the liposome results in a liposome-encapsulated charged toxin. The invention also relates to a pharmaceutical composition comprising said liposomes. A further aspect of the present invention relates to a method of treating patients suffering from endogenous or exogenous toxicopathies, preferably selected from drug, metabolite, pesticide, insecticide, toxin, and chemical warfare toxicopathies, more preferably hyperammonemia, comprising the step of administering liposomes of the invention in a therapeutically effective amount into the peritoneal space of a patient in need thereof. Next to human, the present invention is particularly suitable to veterinary aspects.

The present invention provides active salts of ornithine and aspartate dipeptide compounds, preparation methods thereof, pharmaceutical compositions comprising the active salts, and preparation of the dipeptide compounds or their active salts for preventing or treating hyperemia Use in the medicament of ammonia disease or liver disease, especially hepatic encephalopathy. The test results clearly show that the ornithine and aspartate dipeptide compounds and their active salts of the present invention can significantly reduce blood ammonia concentration after administration, and can significantly improve the memory secondary to TAA-induced liver injury in rats. It means that the dipeptide compound and its active salt have a certain therapeutic effect on hyperammonemia or liver disease, especially hepatic encephalopathy.

Aspects of the disclosure relate to oligosaccharide compositions and methods of making the same. Also provided are methods of using oligosaccharide compositions as microbiome metabolic therapies for reducing ammonia levels and for the treatment of hyperammonemia-related diseases (e.g., urea cycle disorders and hepatic encephalopathy).

The invention proposes the use of dihydroartemisinin in the preparation of medicines, and the medicines are used for preventing or treating hyperammonemia. Therefore, it provides theoretical basis and application value for human or animal hyperammonemia treatment or auxiliary treatment medicine.

The present disclosure relates to a biosensor capable of measuring the total concentration of one or a plurality of ammonia or ammonium ions with the use of indophenol reagents in the presence of an ionomer. In some embodiments, the biosensor comprises a perflurinated membrane that comprises an ionomer in contact with an alkali buffer in a vessel configured to receive a sample, such as whole blood. The disclosure also relates to a method of detecting or quantifying the ammonia or ammonium ion concentration in whole blood in a point of care bio sensor without reliance on gas chromatography or any measurement that takes more than about twenty minutes.

The object of the present invention is to provide a new improvement capable of preventing or delaying the transfer to hemodialysis therapy or reducing the number of implementations of the therapy in the case of renal dysfunction, and preventing or reducing the occurrence of hyperammonemia in the case of liver dysfunction Disease with food. In order to achieve this object, the disease-modifying food of the present invention is characterized by containing indigestible polysaccharides as the main component and limiting the addition of protein components. Thus, by using the energy generated by the absorption of indigestible polysaccharides, the urea or ammonia secreted into the intestines is used as the N source to synthesize bacterial protein, and the proliferated bacterial cells are excreted as feces to reduce the amount of nitrogen in the blood. Low-molecular nitrogen compounds, as a result, can improve renal dysfunction and liver dysfunction.

The invention provides an acylated derivative for an ornithine and aspartate dipeptide compound or an officinal salt thereof, a preparation method thereof, a medicine composition containing the derivative or the officinal salt thereof, and the application of the derivative or the officinal salt thereof for preparing medicines for preventing or curing hyperammonemia or liver diseases, particularlyhepatic encephalopathy. Experimental results definitely indicate that the concentration of blood ammonia can be obviously reduced after administration for the acylated derivative for the ornithine andaspartate dipeptide compound, the acylated derivative takes effect quickly by preferably compared with LOLA, subsequent dysmnesia after TAA-induced rat liver injury can be obviously improved, and theacylated derivative for the dipeptide has a certain treatment effect on hyperammonemia or liver diseases, particularly hepatic encephalopathy.

A material which has excellent ammonia metabolism improving effect and is effective for endurance enhancement, anti-fatigue or the like is provided. An ammonia metabolism promoting agent, comprising catechins and ornithine as active ingredients. An endurance enhancing agent, comprising catechins and ornithine as active ingredients. An anti-fatigue agent, comprising catechins and ornithine as active ingredients. An agent for suppressing a reduction in blood glucose level by exercise, comprising catechins and ornithine as active ingredients. An agent for promoting recovery from reduced blood glucose level by exercise, comprising catechins and ornithine as active ingredients. An agent for suppressing a reduction in muscle glycogen by exercise, comprising catechins and ornithine as active ingredients. A muscle endurance enhancing agent, comprising catechins and ornithine as active ingredients. An agent for preventing or ameliorating hyperammonemia, hepatic encephalopathy or chronic fatigue syndrome, comprising catechins and ornithine as active ingredients.

Some embodiments of the present application are directed to oral formulations of L- ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration route than the standard intravenous administration of L-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, hepatic encephalopathy, or patients with urea cycle disorders.

A compound containing o-naphthalene quinone structure for preparing medicines to prevent and treat hyperammonemia and hepatic encephalopathy is prepared from natural Masonate F through structure reformation and optimization.